Melatonin
Semantic SEO entity — key topical authority signal for Melatonin in Google’s Knowledge Graph
Melatonin is an endogenous hormone (N‑acetyl‑5‑methoxytryptamine) produced by the pineal gland that regulates circadian rhythms and promotes sleep onset. As an over‑the‑counter supplement it is widely used worldwide to treat insomnia, jet lag, shift‑work disorder, and circadian rhythm disturbances. Clinically it matters because it targets the biological clock rather than only producing sedation, making it a first‑line behavioral and chronobiotic adjunct in many cases. For content strategy, melatonin is a high‑intent topical hub that connects dosing, safety, pediatrics, geriatrics, interactions, and regulatory nuance — ideal for authoritative, evidence‑based clusters.
- Chemical name
- N‑acetyl‑5‑methoxytryptamine
- First isolated
- 1958 (Aaron B. Lerner and colleagues)
- Typical OTC adult dose range
- 0.2–10 mg (common effective range 0.5–5 mg; some protocols use 0.3–1 mg for elderly)
- Oral bioavailability
- High interindividual variability: approximately 10–56% reported in pharmacokinetic studies
- Plasma half‑life
- Short: ~30–60 minutes for immediate‑release formulations; prolonged‑release formulations extend effective exposure
- CAS number
- 73‑31‑4
- Onset of action
- Typically 30–60 minutes after oral immediate‑release dosing (timing is critical for circadian effects)
- Approved medicinal product example
- Circadin (prolonged‑release melatonin 2 mg) approved in the EU for primary insomnia in adults aged 55+
Biology & Mechanism of Action
Exogenous melatonin administered at specific clock times can shift circadian phase (advance or delay), making it a chronobiotic rather than a simple sedative in many uses. Timing matters: taking melatonin in the early evening (a few hours before habitual bedtime) tends to advance the circadian phase and is useful for delayed sleep phase disorder; taking it at bedtime primarily promotes sleep onset. Different formulations (immediate vs prolonged release) have distinct pharmacokinetics that determine whether the product primarily affects sleep initiation or helps maintain sleep.
Pharmacokinetics are variable: oral bioavailability is subject to first‑pass hepatic metabolism, and endogenous production declines with age. Genetic and environmental factors (e.g., smoking, concomitant medications that inhibit or induce CYP1A2) alter melatonin clearance. Because melatonin interfaces with the circadian system rather than just central nervous system sedation mechanisms, its clinical effects and recommended use diverge from classic hypnotics.
Clinical Uses and Evidence
In specific populations, melatonin is frequently used: older adults (where endogenous production often falls), children with neurodevelopmental disorders (ASD, ADHD) experiencing insomnia, and shift workers trying to re‑entrain sleep timing. Pediatric use should be supervised by a clinician: randomized trials show benefit in sleep onset for children with neurodevelopmental disorders, but long‑term safety and effects on puberty require monitoring.
Comparative effectiveness: melatonin is not generally as potent as benzodiazepine receptor agonists (e.g., zolpidem) for immediate sedation, but for chronobiotic indication (phase shifting) it is unique. For patients prioritizing short‑term efficacy over long‑term risks, prescription hypnotics may provide larger immediate improvements; for circadian disorders, behavioral approaches plus precisely timed melatonin have clearer mechanistic rationale and favorable risk profiles.
Dosing, Formulations, and Practical Administration
Dosing must align with therapeutic intent. For sleep onset insomnia many clinicians recommend starting low (0.3–1 mg for older adults; 0.5–3 mg for adults) and titrating up as needed, while circadian phase shifting often uses lower doses timed several hours before desired sleep time. High doses (5–10 mg) are commonly used in over‑the‑counter practice, but higher doses do not consistently produce greater phase‑shifting and may increase side effects. Pediatric doses are weight‑adjusted and often much lower — starting at 0.5 mg and titrating by clinical response with specialist oversight.
Timing is as important as dose: to advance circadian phase, take melatonin 3–5 hours before habitual bedtime or according to dim light melatonin onset (DLMO) assessments if available; for general sleep initiation, 30–60 minutes before bedtime is common. Combining melatonin with light therapy (bright light in the morning for phase advance protocols) amplifies circadian effects and is standard in evidence‑based chronotherapy.
Safety, Side Effects, and Drug Interactions
Drug interactions are clinically important. Melatonin metabolism involves CYP1A2 and to lesser extents CYP2C19 and CYP2C9; potent CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin) can dramatically increase melatonin levels, while inducers can lower exposure. Melatonin may potentiate sedative effects when combined with CNS depressants (benzodiazepines, opioids, alcohol) and has theoretical interactions with anticoagulants (warfarin) and immunosuppressants. Patients on multiple medications should review melatonin use with their clinician.
Special populations: in pregnancy and lactation melatonin is usually avoided because of insufficient safety data. In children, short‑term use shows benefit in neurodevelopmental insomnia but requires pediatric oversight and monitoring for daytime effects and potential impacts on sleep architecture and development. Long‑term safety data are limited; stewardship and periodic reassessment are best practice.
Regulatory Status and Marketplace Considerations
Quality and purity issues are common in unregulated supplement markets: independent testing frequently finds variance between labeled and actual melatonin content, presence of impurities, or inconsistent dissolution profiles. For content and clinical guidance, emphasize choosing third‑party tested brands, clear labeling of dose and formulation, and awareness of product variability — especially for pediatric dosing where compounding may be used.
Market dynamics: melatonin is one of the most commonly used sleep supplements worldwide and is heavily promoted online and in retail. This creates both opportunity and risk for content creators: high search volume and transactional interest (buying OTC melatonin) coexist with major consumer confusion about dosing, timing, formulation differences, and safety. Accurate, referenced guidance and buyer's‑guides that emphasize evidence and testing stand out.
Content Strategy: How to Build a Comprehensive Melatonin Hub
SEO and user intent mapping: target high‑volume informational queries (e.g., "melatonin dosage for adults", "how long does melatonin take to work") with concise, evidence‑based pages that include quick dosing charts and decision flowcharts. Transactional pages (product reviews, best melatonin for travel, best sublingual melatonin) should include testing credentials, dose guidance, and disclaimers. Use structured data (FAQ schema, product schema) to improve SERP visibility and capture featured snippets for dosing and onset queries.
Trust signals: cite peer‑reviewed meta‑analyses, guidelines (e.g., AASM statements on insomnia), and regulatory approvals (Circadin particulars). For conversion funnels, combine educational content with product quality guidance and clinician consultation prompts. Cover clinical controversy and gaps (long‑term safety, pediatric puberty effects) transparently — this builds E‑A‑T and reduces misinformation risk.
Content Opportunities
Frequently Asked Questions
How much melatonin should I take to sleep?
Start low and titrate: many adults respond to 0.5–3 mg for sleep onset; elderly patients often benefit from 0.3–1 mg. Higher OTC doses (5–10 mg) are commonly used but may increase side effects and do not proportionally increase phase‑shifting effects.
How long does melatonin take to work?
Immediate‑release melatonin typically begins to act within 30–60 minutes, so most people take it about half an hour before bedtime. For circadian phase shifting, melatonin is timed hours before desired sleep to achieve a phase advance.
Is melatonin safe to take every night?
Short‑term nightly use is generally well tolerated, but long‑term safety data are limited. Regular review with a clinician is recommended, particularly for children, adolescents, pregnant or breastfeeding people, and those on multiple medications.
Can melatonin make you groggy in the morning?
Yes — excessive dose or inappropriate timing can cause next‑day drowsiness. Using the lowest effective dose, selecting the right formulation (immediate vs prolonged release), and timing 30–60 minutes before sleep reduces morning grogginess.
Can children take melatonin?
Melatonin can help children with insomnia, especially those with neurodevelopmental disorders, but dosing and duration should be guided by a pediatrician. Use the lowest effective dose and monitor for daytime sleepiness or behavioral changes.
Does melatonin interact with medications?
Yes. Melatonin is metabolized mainly by CYP1A2; CYP1A2 inhibitors (e.g., fluvoxamine) can raise melatonin levels. It can also interact with anticoagulants, immunosuppressants, and CNS depressants. Check with a clinician or pharmacist if you take prescription drugs.
Is melatonin addictive?
Melatonin is not considered addictive and does not produce tolerance in the same way as benzodiazepines. However, psychological reliance or habit formation around use can occur; address underlying sleep hygiene and circadian issues.
Topical Authority Signal
Thoroughly covering melatonin signals domain expertise in chronobiology, sleep medicine, and safe supplement use, which strengthens E‑A‑T for a sleep or supplement site. A comprehensive melatonin hub unlocks topical authority across related queries — dosing, timing, interactions, pediatric and geriatric guidance, product quality, and circadian therapy — enabling structured internal linking and featured snippet capture.